Andrea Cervi, MD; James Douketis, MD
Cervi A, Douketis J. In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days. Ann Intern Med. 2019;170:JC67. doi: 10.7326/ACPJ201906180-067
Download citation file:
Published: Ann Intern Med. 2019;170(12):JC67.
Hematology/Oncology, Venous Thromboembolism.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use